Skip to content
PubMed This is a summary of 62 peer-reviewed journal articles Updated

Research & Literature

Explore the leading researchers and institutions driving advances in this area, and dive into the full body of literature that informs this resource.

Explore the Literature Visualize citation networks across 62 referenced papers

Top Authors

Indraneel Banerjee
University of Manchester
Diva D. De León
Children's Hospital of Philadelphia
Chris Worth
Royal Manchester Children's Hospital
Maria Salomon‐Estebanez
Royal Manchester Children's Hospital
Sarah Elizabeth Flanagan
University of Exeter
Charles A. Stanley
Children's Hospital of Philadelphia
Antonia Dastamani
Great Ormond Street Hospital
Jayne Houghton
Royal Devon & Exeter NHS Foundation Trust
Kara E. Boodhansingh
Children's Hospital of Philadelphia
Senthil Senniappan
Alder Hey Children's Hospital

Top Institutions

Ranked by publications Top 10 institutions
09

Alder Hey Children's Hospital

Liverpool, United Kingdom

11 papers
10

University of Eastern Finland

Kuopio, Finland

8 papers

References

References (62)
  1. 1

    Hyperinsulinemic hypoglycemia: think of hyperinsulinism/hyperammonemia (HI/HA) syndrome caused by mutations in the GLUD1 gene.

    Tran C, Konstantopoulou V, Mecjia M, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2015; (28(7-8)):873-6.

    PMID: 25781533
  2. 2

    Hyperinsulinemic Hypoglycemia.

    Güemes M, Hussain K

    Pediatric clinics of North America 2015; (62(4)):1017-36.

    PMID: 26210630
  3. 3

    Biomarkers of Insulin for the Diagnosis of Hyperinsulinemic Hypoglycemia in Infants and Children.

    Ferrara C, Patel P, Becker S, et al.

    The Journal of pediatrics 2016; (168()):212-219 doi:10.1016/j.jpeds.2015.09.045.

    PMID: 26490124
  4. 4

    A novel mutation in the glutamate dehydrogenase (GLUD1) of a patient with congenital hyperinsulinism-hyperammonemia (HI/HA).

    Fang C, Ding X, Huang Y, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2016; (29(3)):385-8.

    PMID: 26656609
  5. 5

    Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders.

    Stanley CA

    The Journal of clinical endocrinology and metabolism 2016; (101(3)):815-26 doi:10.1210/jc.2015-3651.

    PMID: 26908106
  6. 6

    Hyperinsulinism-hyperammonemia syndrome: a de novo mutation of the GLUD1 gene in twins and a review of the literature.

    Ninković D, Sarnavka V, Bašnec A, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2016; (29(9)):1083-8.

    PMID: 27383869
  7. 7

    Robust regulation of hepatic pericentral amination by glutamate dehydrogenase kinetics.

    Bera S, Lamba S, Rashid M, et al.

    Integrative biology : quantitative biosciences from nano to macro 2016; (8(11)):1126-1132 doi:10.1039/c6ib00158k.

    PMID: 27747338
  8. 8

    A severe case of hyperinsulinism due to hemizygous activating mutation of glutamate dehydrogenase.

    Barrosse-Antle M, Su C, Chen P, et al.

    Pediatric diabetes 2017; (18(8)):911-916 doi:10.1111/pedi.12507.

    PMID: 28165182
  9. 9

    Diagnosis of congenital hyperinsulinism: Biochemical profiles during hypoglycemia.

    Sakakibara A, Hashimoto Y, Kawakita R, et al.

    Pediatric diabetes 2018; (19(2)):259-264 doi:10.1111/pedi.12548.

    PMID: 28597971
  10. 10

    Seizures and diagnostic difficulties in hyperinsulinism-hyperammonemia syndrome.

    Aka S, Alanay Y, Boodhansingh KE, et al.

    The Turkish journal of pediatrics 2016; (58(5)):541-544.

    PMID: 28621098
  11. 11

    Development of Pulmonary Hypertension During Treatment with Diazoxide: A Case Series and Literature Review.

    Timlin MR, Black AB, Delaney HM, et al.

    Pediatric cardiology 2017; (38(6)):1247-1250 doi:10.1007/s00246-017-1652-3.

    PMID: 28642988
  12. 12

    Efficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registry.

    Hosokawa Y, Kawakita R, Yokoya S, et al.

    Endocrine journal 2017; (64(9)):867-880 doi:10.1507/endocrj.EJ17-0024.

    PMID: 28701683
  13. 13

    Both Low Blood Glucose and Insufficient Treatment Confer Risk of Neurodevelopmental Impairment in Congenital Hyperinsulinism: A Multinational Cohort Study.

    Helleskov A, Melikyan M, Globa E, et al.

    Frontiers in endocrinology 2017; (8()):156 doi:10.3389/fendo.2017.00156.

    PMID: 28740482
  14. 14

    Identification of the molecular dysfunction caused by glutamate dehydrogenase S445L mutation responsible for hyperinsulinism/hyperammonemia.

    Grimaldi M, Karaca M, Latini L, et al.

    Human molecular genetics 2017; (26(18)):3453-3465 doi:10.1093/hmg/ddx213.

    PMID: 28911206
  15. 15

    Glutamate dehydrogenase: role in regulating metabolism and insulin release in pancreatic β-cells.

    Wilson DF, Cember ATJ, Matschinsky FM

    Journal of applied physiology (Bethesda, Md. : 1985) 2018; (125(2)):419-428 doi:10.1152/japplphysiol.01077.2017.

    PMID: 29648519
  16. 16

    Safety and effectiveness, including intelligence prognosis, of diazoxide in pediatric patients with hyperinsulinemic hypoglycemia: special survey in Japan (long-term, all-case survey).

    Fukutomi M, Shimodera M, Maeda Y, et al.

    Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 2018; (27(3)):131-143 doi:10.1297/cpe.27.131.

    PMID: 30083030
  17. 17

    The effect of hypoglycaemia on neurocognitive outcome in children and adolescents with transient or persistent congenital hyperinsulinism.

    Muukkonen L, Männistö J, Jääskeläinen J, et al.

    Developmental medicine and child neurology 2019; (61(4)):451-457 doi:10.1111/dmcn.14039.

    PMID: 30246438
  18. 18

    Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide.

    Herrera A, Vajravelu ME, Givler S, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(12)):4365-4372 doi:10.1210/jc.2018-01613.

    PMID: 30247666
  19. 19

    Clinical and Molecular Spectrum of Glutamate Dehydrogenase Gene Defects in 26 Chinese Congenital Hyperinsulinemia Patients.

    Su C, Liang XJ, Li WJ, et al.

    Journal of diabetes research 2018; (2018()):2802540 doi:10.1155/2018/2802540.

    PMID: 30306091
  20. 20

    The Effect of Continuous Intravenous Glucagon on Glucose Requirements in Infants with Congenital Hyperinsulinism.

    Hawkes CP, Lado JJ, Givler S, De Leon DD

    JIMD reports 2019; (45()):45-50 doi:10.1007/8904_2018_140.

    PMID: 30311139
  21. 21

    Hyperinsulinism-hyperammonemia Syndrome in an Infant with Seizures.

    Strajnar A, Tansek MZ, Podkrajsek KT, et al.

    Balkan journal of medical genetics : BJMG 2018; (21(1)):77-81 doi:10.2478/bjmg-2018-0014.

    PMID: 30425915
  22. 22

    Congenital Hyperinsulinemic Hypoglycemia and Hyperammonemia due to Pathogenic Variants in GLUD1.

    Roy K, Satapathy AK, Houhton JAL, et al.

    Indian journal of pediatrics 2019; (86(11)):1051-1053 doi:10.1007/s12098-019-02980-x.

    PMID: 31119523
  23. 23

    Diazoxide-induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: Recommendations from a multicentre study in the United Kingdom.

    Chen SC, Dastamani A, Pintus D, et al.

    Clinical endocrinology 2019; (91(6)):770-775 doi:10.1111/cen.14096.

    PMID: 31520536
  24. 24

    Hyperinsulinism associated with GLUD1 mutation: allosteric regulation and functional characterization of p.G446V glutamate dehydrogenase.

    Luczkowska K, Stekelenburg C, Sloan-Béna F, et al.

    Human genomics 2020; (14(1)):9 doi:10.1186/s40246-020-00262-8.

    PMID: 32143698
  25. 25

    Continuous Glucose Monitoring Systems: Are They Useful for Evaluating Glycemic Control in Children with Hyperinsulinism?

    Rayannavar A, Elci OU, Mitteer L, De León DD

    Hormone research in paediatrics 2019; (92(5)):319-327 doi:10.1159/000506230.

    PMID: 32208390
  26. 26

    Hyperinsulinism hyperammonaemia (HI/HA) syndrome due to GLUD1 mutation: phenotypic variations ranging from late presentation to spontaneous resolution.

    Brandt A, Agarwal N, Giri D, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2020; (33(5)):675-679.

    PMID: 32229669
  27. 27

    Pericardial Effusion Associated with Diazoxide Treatment for Congenital Hyperinsulinism.

    Hastings LA, Preddy J, McCready M, et al.

    Hormone research in paediatrics 2020; (93(3)):206-211 doi:10.1159/000507624.

    PMID: 32580193
  28. 28

    Efficacy of Dose-Titrated Glucagon Infusions in the Management of Congenital Hyperinsulinism: A Case Series.

    Salomon-Estebanez M, Yau D, Dunne MJ, et al.

    Frontiers in endocrinology 2020; (11()):441 doi:10.3389/fendo.2020.00441.

    PMID: 33013678
  29. 29

    Visual interpretation, not SUV ratios, is the ideal method to interpret 18F-DOPA PET scans to aid in the cure of patients with focal congenital hyperinsulinism.

    Garg PK, Putegnat B, Truong L, et al.

    PloS one 2020; (15(10)):e0241243 doi:10.1371/journal.pone.0241243.

    PMID: 33108363
  30. 30

    Risk Factors for Adverse Neurodevelopment in Transient or Persistent Congenital Hyperinsulinism.

    Roeper M, Salimi Dafsari R, Hoermann H, et al.

    Frontiers in endocrinology 2020; (11()):580642 doi:10.3389/fendo.2020.580642.

    PMID: 33424766
  31. 31

    Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: A systematic review and meta-analysis.

    Chen X, Feng L, Yao H, et al.

    PloS one 2021; (16(2)):e0246463 doi:10.1371/journal.pone.0246463.

    PMID: 33571197
  32. 32

    A Sensitive Plasma Insulin Immunoassay to Establish the Diagnosis of Congenital Hyperinsulinism.

    Siersbæk J, Larsen AR, Nybo M, Christesen HT

    Frontiers in endocrinology 2020; (11()):614993 doi:10.3389/fendo.2020.614993.

    PMID: 33679602
  33. 33

    Congenital Hyperinsulinism.

    Sims K

    NeoReviews 2021; (22(4)):e230-e240 doi:10.1542/neo.22-4-e230.

    PMID: 33795398
  34. 34

    18F-6-Fluoro-l-Dopa PET/CT Imaging of Congenital Hyperinsulinism.

    States LJ, Davis JC, Hamel SM, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2021; (62(Suppl 2)):51S-56S doi:10.2967/jnumed.120.246033.

    PMID: 34230074
  35. 35

    PNC2 (SLC25A36) Deficiency Associated With the Hyperinsulinism/Hyperammonemia Syndrome.

    Shahroor MA, Lasorsa FM, Porcelli V, et al.

    The Journal of clinical endocrinology and metabolism 2022; (107(5)):1346-1356 doi:10.1210/clinem/dgab932.

    PMID: 34971397
  36. 36

    Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families.

    Banerjee I, Raskin J, Arnoux JB, et al.

    Orphanet journal of rare diseases 2022; (17(1)):61 doi:10.1186/s13023-022-02214-y.

    PMID: 35183224
  37. 37

    Anxiety, depression, and quality of life in parents of children with congenital hyperinsulinism.

    Roeper M, Hoermann H, Salimi Dafsari R, et al.

    European journal of pediatrics 2022; (181(7)):2779-2788 doi:10.1007/s00431-022-04486-9.

    PMID: 35507217
  38. 38

    Congenital Hyperinsulinism International: A Community Focused on Improving the Lives of People Living With Congenital Hyperinsulinism.

    Raskin J, Pasquini TLS, Bose S, et al.

    Frontiers in endocrinology 2022; (13()):886552 doi:10.3389/fendo.2022.886552.

    PMID: 35573986
  39. 39

    Characterizing the neurological phenotype of the hyperinsulinism hyperammonemia syndrome.

    Rosenfeld E, Nanga RPR, Lucas A, et al.

    Orphanet journal of rare diseases 2022; (17(1)):248 doi:10.1186/s13023-022-02398-3.

    PMID: 35752848
  40. 40

    Congenital Hyperinsulinism: Current Laboratory-Based Approaches to the Genetic Diagnosis of a Heterogeneous Disease.

    Hewat TI, Johnson MB, Flanagan SE

    Frontiers in endocrinology 2022; (13()):873254 doi:10.3389/fendo.2022.873254.

    PMID: 35872984
  41. 41

    Families' Experiences of Continuous Glucose Monitoring in the Management of Congenital Hyperinsulinism: A Thematic Analysis.

    Auckburally SH, Worth C, Salomon-Estebanez M, et al.

    Frontiers in endocrinology 2022; (13()):894559 doi:10.3389/fendo.2022.894559.

    PMID: 35928891
  42. 42

    Spectrum of neuro-developmental disorders in children with congenital hyperinsulinism due to activating mutations in GLUD1.

    Aftab S, Gubaeva D, Houghton JAL, et al.

    Endocrine connections 2023; (12(4)).

    PMID: 35951311
  43. 43

    Mosaic GLUD1 Mutations Associated with Hyperinsulinism Hyperammonemia Syndrome.

    Boodhansingh KE, Rosenfeld E, Lord K, et al.

    Hormone research in paediatrics 2022; (95(5)):492-498 doi:10.1159/000526203.

    PMID: 35952631
  44. 44

    Congenital hyperinsulinism in clinical practice: From biochemical pathophysiology to new monitoring techniques.

    Martino M, Sartorelli J, Gragnaniello V, Burlina A

    Frontiers in pediatrics 2022; (10()):901338 doi:10.3389/fped.2022.901338.

    PMID: 36210928
  45. 45

    Congenital Hyperinsulinaemic Hypoglycaemia-A Review and Case Presentation.

    Krawczyk S, Urbanska K, Biel N, et al.

    Journal of clinical medicine 2022; (11(20)) doi:10.3390/jcm11206020.

    PMID: 36294341
  46. 46

    The hypoglycaemia error grid: A UK-wide consensus on CGM accuracy assessment in hyperinsulinism.

    Worth C, Dunne MJ, Salomon-Estebanez M, et al.

    Frontiers in endocrinology 2022; (13()):1016072 doi:10.3389/fendo.2022.1016072.

    PMID: 36407313
  47. 47

    Hyperinsulinism-hyperammonemia syndrome in two Peruvian children with refractory epilepsy.

    De Los Santos-La Torre MA, Del Águila-Villar CM, Lu-de Lama LR, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2023; (36(2)):207-211 doi:10.1515/jpem-2022-0490.

    PMID: 36476334
  48. 48

    The behaviour change behind a successful pilot of hypoglycaemia reduction with HYPO-CHEAT.

    Worth C, Nutter PW, Salomon-Estebanez M, et al.

    Digital health 2023; (9()):20552076231192011 doi:10.1177/20552076231192011.

    PMID: 37545627
  49. 49

    Congenital Hyperinsulinism - Notes for the General Pediatrician.

    Estebanez MS, Worth C, Banerjee I

    Indian pediatrics 2024; (61(6)):578-584.

    PMID: 38584412
  50. 50

    Octreotide efficacy and safety in children with hyperinsulinism: evidence from two Chinese centers.

    Ni J, Cao B, Zeng H, et al.

    European journal of pediatrics 2024; (184(1)):33 doi:10.1007/s00431-024-05884-x.

    PMID: 39565408
  51. 51

    Reverse Phenotyping: Addressing Refractory Seizures From an Endocrine Perspective.

    Sherin S, Soodhana D, Mohanlal S, Pachat D

    Cureus 2024; (16(12)):e75146 doi:10.7759/cureus.75146.

    PMID: 39759686
  52. 52

    Large copy number variants are an important cause of congenital hyperinsulinism that should be screened for during routine testing.

    Flanagan SE, Lazaridi IA, Männistö JME, et al.

    Frontiers in endocrinology 2025; (16()):1514916 doi:10.3389/fendo.2025.1514916.

    PMID: 40041288
  53. 53

    Continuous Glucose Monitoring in the Management of Congenital Hyperinsulinism: A National User-satisfaction Survey, UK.

    Couch H, Pearson A, Malhotra N, et al.

    The Journal of clinical endocrinology and metabolism 2025; (111(1)):139-148 doi:10.1210/clinem/dgaf313.

    PMID: 40418653
  54. 54

    Case Report: Food-based enteral formula in the nutritional management of children with hyperinsulinism: single center retrospective case series.

    O'Connor G, Cheng L, Cunjamalay A

    Frontiers in endocrinology 2025; (16()):1574093 doi:10.3389/fendo.2025.1574093.

    PMID: 41079202
  55. 55

    Trisomy 13 as a risk factor for pulmonary hypertension induced by diazoxide.

    Ishikawa K, Nakao H, Shinjo D, et al.

    Annals of pediatric cardiology 2025; (18(4)):351-356 doi:10.4103/apc.apc_65_25.

    PMID: 41725869
  56. 56

    Comprehensive genetic rescreening improves diagnostic yield in congenital hyperinsulinism.

    Männistö JME, Houghton JAL, Bennett JJ, et al.

    Journal of the Endocrine Society 2026; (10(4)):bvag047 doi:10.1210/jendso/bvag047.

    PMID: 41924297
  57. 57

    Natural History of the Hyperinsulinism/Hyperammonemia Syndrome: A Retrospective Review Incorporating Patient-Centered Data.

    Rosenfeld E, Taylor O, Mitteer LM, et al.

    Hormone research in paediatrics 2026; 1-11 doi:10.1159/000551535.

    PMID: 41980002
  58. 58

    From standard to individualized diazoxide therapy in congenital hyperinsulinism: a narrative review.

    Wong T, Chan D, Chua C, et al.

    Frontiers in pharmacology 2026; (17()):1781424 doi:10.3389/fphar.2026.1781424.

    PMID: 41982675
  59. 59

    Low-level mosaic variants causing the pancreatic disease congenital hyperinsulinism can be detected from blood DNA.

    Bennett JJ, Laver TW, Männistö JME, et al.

    EBioMedicine 2026; (128()):106308 doi:10.1016/j.ebiom.2026.106308.

    PMID: 42184599
  60. 60

    Real-world insights into neurodevelopmental outcomes amongst people with congenital hyperinsulinism.

    Lopez LN, Banerjee I, De Leon DD, et al.

    Orphanet journal of rare diseases 2026; (21(1)).

    PMID: 42399951
  61. 61

    Inpatient continuous glucose monitoring halves the risk of hypoglycemia in patients with hyperinsulinism.

    Chandra C, De Silva S, Worthington S, et al.

    Frontiers in endocrinology 2026; (17()):1943475 doi:10.3389/fendo.2026.1943475.

    PMID: 42959150
  62. 62

    Parent experiences of infant feeding in congenital hyperinsulinism: a thematic analysis.

    Worthington S, Ginbey E, Otabor O, et al.

    Frontiers in endocrinology 2026; (17()):1955679 doi:10.3389/fendo.2026.1955679.

    PMID: 42978621